Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Conditions: Hepatocellular Carcinoma; Chemotherapy Effect; Chemotherapeutic Toxicity Interventions: Drug: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU; Drug: Concurrent Lenvatinib; Drug: Concurrent PD-1 antibody; Drug: Sequential Lenvatinib; Drug: Sequential PD-1 antibody Sponsors: Sun Yat-sen University; The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine; Affiliated Hospital of Guangdong Medical University; First People's Hospital of Foshan Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Calcium | Cancer & Oncology | Carcinoma | China Health | Eloxatin | Hospitals | Immunotherapy | Research | Toxicology | Vitamin B9